Minneapolis, MN, April 14, 2026 (GLOBE NEWSWIRE) -- NightWare, Inc. and Exit 156 Capital today jointly announced a strategic investment by Exit 156 in NightWare's ongoing Series C financing. NightWare is the maker of the only FDA-cleared prescription digital therapeutic indicated for nightmare disorder in adults with post-traumatic stress disorder (PTSD). The partnership unites a Minneapolis-based growth-stage digital health company with a Minneapolis-area investment firm whose expertise spans healthcare services, devices, and technology, deepening a relationship that began with Exit 156 Founding Partner Mike Nathan's early involvement as a NightWare investor and advisor.

The investment will accelerate NightWare's national VA Pathfinder Innovation Pilot, scale commercial employer-group insurance pilots with first responder organizations, advance proprietary hardware development, and expand the company's patient management program toward a recurring revenue model. NightWare's Series C is being raised at a $10 million pre-money valuation, with $1.4 million already secured and $2.0 million of equity remaining available to qualified investors.

A Partnership Rooted in Mission and Market Conviction

The NightWare-Exit 156 partnership reflects shared conviction about both the severity of the unmet clinical need and the strength of the commercial foundation NightWare has built. Nightmare disorder affects an estimated 71–96% of individuals with PTSD and is independently associated with suicidality, yet most PTSD treatment protocols do not include a device-based intervention specifically targeting nightmares. NightWare addresses this gap with an FDA-cleared, AI-guided wearable system that intervenes during the nightmare cycle, without waking the patient.

For Exit 156, the investment fits squarely within the firm's focus on healthcare technology companies with defensible market positions and proven management teams. For NightWare, Exit 156 brings not only capital but a network of healthcare operating partners, a flat and decisive investment structure, and two decades of experience building and scaling healthcare companies in the Minneapolis ecosystem.

"Exit 156 doesn't invest in categories, they invest in people and proof. We have both. This partnership accelerates our path to standard reimbursement coverage in the VA, deeper penetration in first responder markets, and the commercial infrastructure needed to make NightWare the standard of care for nightmare disorder nationwide."

— Matt Tucker, CEO, NightWare, Inc.

"Mike Nathan's early belief in NightWare helped set the stage for ...